Your session is about to expire
What is Rytary
LevodopaThe Generic name of this drug
Treatment SummaryCarbidopa is a medication used to prevent nausea in patients taking levodopa. It works by blocking the enzyme aromatic amino acid decarboxylase, which helps to reduce levels of nausea. Carbidopa is often used in combination with levodopa, but a single-ingredient formulation was approved by the FDA in 2014. The combination treatment of carbidopa/levodopa was first developed by Watson Labs, but the FDA approved Mayne Pharma's version of this combination therapy in 1992.
Sinemetis the brand name
Rytary Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Levodopa
1975
272
Approved as Treatment by the FDA
Levodopa, also called Sinemet, is approved by the FDA for 6 uses including manganese intoxication and Parkinsonism post encephalitic .manganese intoxication
Used to treat manganese intoxication in combination with Carbidopa
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Carbidopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinsonism
Used to treat Parkinsonism in combination with Carbidopa
Paralysis agitans
Used to treat Paralysis agitans in combination with Carbidopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Carbidopa
Effectiveness
How Rytary Affects PatientsWhen taken with levodopa, carbidopa prevents levodopa from being converted to dopamine and serotonin in the body, instead allowing more to reach the brain. This increases the amount of levodopa in the body, which can help alleviate symptoms for a period of time. Carbidopa also increases the half-life of levodopa, allowing it to be effective for longer, and reduces the need for levodopa, as well as side effects like nausea.
How Rytary works in the bodyCarbidopa is a drug that stops an important enzyme called DDC from breaking down levodopa. DDC is found in the body and in the barrier between the blood and the brain. Carbidopa works mainly outside the brain, preventing levodopa from being broken down. This means that more levodopa can reach the brain, where it can be converted into dopamine.
When to interrupt dosage
The prescribed dosage of Rytary is contingent upon the identified condition, such as Symptomatic Parkinson Disease, carbon monoxide intoxication and Parkinson's Disease. The measure of dosage differs, in accordance with the method of delivery specified in the table underneath.Condition
Dosage
Administration
Parkinsonism
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
advanced Motor fluctuations
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
carbon monoxide intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
manganese intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinson's Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Restless Legs Syndrome (RLS)
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Paralysis agitans
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinsonism post encephalitic
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Warnings
Rytary has two contraindications, so it must not be administered in combination with the conditions identified in the following table.Rytary ContraindicationsCondition
Risk Level
Notes
Malignant Neoplasms
Do Not Combine
Pulse Frequency
Do Not Combine
cutaneous lesions
Do Not Combine
Common Rytary Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Levodopa.
Methylene blue
Major
Levodopa may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Levodopa may increase the serotonergic activities of Mirtazapine.
Rytary Toxicity & Overdose RiskThe most toxic dose of carbidopa found in rats was 4810mg/kg. Animal studies have not found any evidence that carbidopa can cause cancer or fertility issues. If someone is suspected of overdosing on carbidopa, they should have their stomach pumped and be given intravenous fluids, while their heart rate is monitored.
Rytary Novel Uses: Which Conditions Have a Clinical Trial Featuring Rytary?
49 active clinical trials are currently being conducted to assess the potential of Rytary to alleviate Parkinsonism post Encephalitic, Levodopa-Induced Nausea and Vomiting and Manganese Intoxication.Condition
Clinical Trials
Trial Phases
Parkinson's Disease
46 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
manganese intoxication
0 Actively Recruiting
Paralysis agitans
0 Actively Recruiting
Restless Legs Syndrome (RLS)
1 Actively Recruiting
Not Applicable
advanced Motor fluctuations
0 Actively Recruiting
Parkinsonism post encephalitic
0 Actively Recruiting
Parkinsonism
3 Actively Recruiting
Phase 4
carbon monoxide intoxication
0 Actively Recruiting
Rytary Reviews: What are patients saying about Rytary?
5Patient Review
7/26/2017 Rytary has done wonders for my quality of life. I'm on the lowest dosage and it's still effective after two years, which is amazing.
4.7Patient Review
11/19/2021 I originally was prescribed Sinemet, but the nausea it caused was unbearable. I changed doctors and started taking Rytary a few months ago and have found that my symptoms are much more manageable. I only experience minimal nausea now.
4.3Patient Review
9/16/2018 This medication has helped me a lot in just two weeks. I feel like the tension that had been building up for years has dissipated and I can finally think more clearly. There are still some kinks to work out, but overall I'm feeling much better.
4Patient Review
6/28/2015 This medication is improved my life, but it's not perfect. It can be tricky to find the right dose, and it doesn't work well if I eat too close to taking it.
4Patient Review
10/7/2016 I was given samples of this medication to try out, and instructed to take one capsule three times a day for the first week. If I experienced no problems, I was then supposed to increase the dosage to two capsules three times a day. I saw no difference in my tremors between this medication and the carbidopa/levodopa 25/100 that I had been taking at a lower dosage, and there were no periods where the medication wasn't effective.
4Patient Review
5/13/2016 This treatment effectively eliminated or suppressed many of the traits associated with Parkinson's disease. It also improved my balance and other known problems related to Parkinson's.
4Patient Review
6/7/2020 I was diagnosed with PD at 62 and am now 78. I take 8 capsules of Rytary 245 daily along with carbidopa/levodopa 25/100 as needed. It's the best extender I've found so far; before this, I was getting too much dyskinesia. The cost is very high, even with my Medicare advantage plan--over $500 per month when in the drug coverage gap.
4Patient Review
6/21/2015 The extended release of this medication is more effective than the carb/levo combinations I've tried in the past. With Rytary, I only have to take 3 pills 4 times a day as opposed to 5 pills 5 times a day with carb/levo. Some days I'm almost totally symptom-free, but if I have a stressful day my symptoms come back worse. The upside is that I've started being able to smell again; the other day I smelled chicken cooking and it was amazing!
2.7Patient Review
6/12/2015 The symptoms never resolved themselves.
Patient Q&A Section about rytary
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How long does it take for Rytary to kick in?
"Rytary begins to work on Parkinson's symptoms within an hour, and blood levels remain high for 4-5 hours before gradually decreasing."
Answered by AI
What are the side effects of Rytary?
"These side effects may occur: dizziness, nausea, vomiting, dry mouth, trouble sleeping, unusual dreams, or headache. If any of these effects continue or worsen, tell your doctor or pharmacist. To reduce the risk of dizziness and lightheadedness, get up slowly from a sitting or lying position."
Answered by AI
What does Rytary do for Parkinson's?
"The drug Rytary may help to decrease the amount of time each day when symptoms are not controlled for people with Parkinson's."
Answered by AI
Is Rytary better than Sinemet?
"There are three main types of medication for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease)--Rytary, Sinemet (immediate release), and Sinemet CR (controlled release). The main difference between them is how long each lasts in the body. Rytary lasts the longest, followed by Sinemet CR, with Sinemet (immediate release) having the shortest duration. This means that Ryatary is better at controlling Parkinson's symptoms for longer periods of time and there is less time between doses when the medication wears off."
Answered by AI